Triglyceride-inflammation score established on account of random survival forest for predicting survival in patients with nasopharyngeal carcinoma: a retrospective study

Front Immunol. 2024 Apr 26:15:1375931. doi: 10.3389/fimmu.2024.1375931. eCollection 2024.

Abstract

Objective: This study aimed to establish an effective prognostic model based on triglyceride and inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR), to predict overall survival (OS) in patients with nasopharyngeal carcinoma (NPC). Additionally, we aimed to explore the interaction and mediation between these biomarkers in their association with OS.

Methods: A retrospective review was conducted on 259 NPC patients who had blood lipid markers, including triglyceride and total cholesterol, as well as parameters of peripheral blood cells measured before treatment. These patients were followed up for over 5 years, and randomly divided into a training set (n=155) and a validation set (n=104). The triglyceride-inflammation (TI) score was developed using the random survival forest (RSF) algorithm. Subsequently, a nomogram was created. The performance of the prognostic model was measured by the concordance index (C-index), time-dependent receiver operating characteristic (ROC) curve, and decision curve analysis (DCA). The interaction and mediation between the biomarkers were further analyzed. Bioinformatics analysis based on the GEO dataset was used to investigate the association between triglyceride metabolism and immune cell infiltration.

Results: The C-index of the TI score was 0.806 in the training set, 0.759 in the validation set, and 0.808 in the entire set. The area under the curve of time-dependent ROC of TI score in predicting survival at 1, 3, and 5 years were 0.741, 0.847, and 0.871 respectively in the training set, and 0.811, 0.837, and 0.758 in the validation set, then 0.771, 0.848, and 0.862 in the entire set, suggesting that TI score had excellent performance in predicting OS in NPC patients. Patients with stage T1-T2 or M0 had significantly lower TI scores, NLR, and PLR, and higher LMR compared to those with stage T3-T3 or M1, respectively. The nomogram, which integrated age, sex, clinical stage, and TI score, demonstrated good clinical usefulness and predictive ability, as evaluated by the DCA. Significant interactions were found between triglyceride and NLR and platelet, but triglyceride did not exhibit any medicating effects in the inflammatory markers. Additionally, NPC tissues with active triglyceride synthesis exhibited high immune cell infiltration.

Conclusion: The TI score based on RSF represents a potential prognostic factor for NPC patients, offering convenience and economic advantages. The interaction between triglyceride and NLR may be attributed to the effect of triglyceride metabolism on immune response.

Keywords: inflammation; lipid; nasopharyngeal carcinoma; nomogram; prognosis; triglyceride.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / blood
  • Blood Platelets / immunology
  • Blood Platelets / metabolism
  • Female
  • Humans
  • Inflammation / blood
  • Inflammation / immunology
  • Lymphocytes / immunology
  • Lymphocytes / metabolism
  • Male
  • Middle Aged
  • Nasopharyngeal Carcinoma* / blood
  • Nasopharyngeal Carcinoma* / diagnosis
  • Nasopharyngeal Carcinoma* / immunology
  • Nasopharyngeal Carcinoma* / mortality
  • Nasopharyngeal Neoplasms / blood
  • Nasopharyngeal Neoplasms / diagnosis
  • Nasopharyngeal Neoplasms / immunology
  • Nasopharyngeal Neoplasms / mortality
  • Neutrophils / immunology
  • Neutrophils / metabolism
  • Nomograms*
  • Prognosis
  • ROC Curve
  • Retrospective Studies
  • Triglycerides* / blood

Substances

  • Triglycerides
  • Biomarkers, Tumor

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China (U22A20322 to ZZ, 82202512 to XZ, 81860601 to YC), the Key Laboratory of High-Incidence-Tumor Prevention & Treatment of Guangxi (GKE-ZZ-202305 to XZ).